Phase 1 Clinical Development of IO-202, A First-in-Class Antibody Targeting LILRB4, for the Treatment of AML with Monocytic Differentiation and CMML
Grant Award Details
Grant Type:
Grant Number:
CLIN2-12149
Investigator(s):
Disease Focus:
Human Stem Cell Use:
Award Value:
$6,000,000
Status:
Closed
Progress Reports
Reporting Period:
Final Operational Milestone #5
Grant Application Details
Application Title:
Phase 1 Clinical Development of IO-202, A First-in-Class Antibody Targeting LILRB4, for the Treatment of AML with Monocytic Differentiation and CMML
Public Abstract:
Therapeutic Candidate or Device
IO-202, a first-in-class antibody targeting leukocyte immunoglobulin-like receptor B4 (LILRB4), an immune inhibitory receptor
Indication
Acute myeloid leukemia (AML) with monocytic differentiation and chronic myelomonocytic leukemia (CMML)
Therapeutic Mechanism
IO-202 is the first T-cell activator for AML. Preclinical studies showed that IO-202 can convert a “don’t kill me” to “kill me” signal by activating T cell killing of AML cells and a “don’t find me” to “find me” signal by inhibiting leukemia infiltration.
Unmet Medical Need
AML is the most common acute leukemia in adults. Nearly 20,000 new cases are expected in the U.S. in 2020. Despite advances in treatment, less than 30 percent of AML patients are alive five years after initial diagnosis. CMML is a malignant hematopoietic stem cell disorder with dismal survival.
Project Objective
Proposed Phase 1 study completed
Major Proposed Activities
Conduct a Phase 1 study to evaluate IO-202 in relapsed/refractory patients with AML with monocytic differentiation and CMML.
IO-202, a first-in-class antibody targeting leukocyte immunoglobulin-like receptor B4 (LILRB4), an immune inhibitory receptor
Indication
Acute myeloid leukemia (AML) with monocytic differentiation and chronic myelomonocytic leukemia (CMML)
Therapeutic Mechanism
IO-202 is the first T-cell activator for AML. Preclinical studies showed that IO-202 can convert a “don’t kill me” to “kill me” signal by activating T cell killing of AML cells and a “don’t find me” to “find me” signal by inhibiting leukemia infiltration.
Unmet Medical Need
AML is the most common acute leukemia in adults. Nearly 20,000 new cases are expected in the U.S. in 2020. Despite advances in treatment, less than 30 percent of AML patients are alive five years after initial diagnosis. CMML is a malignant hematopoietic stem cell disorder with dismal survival.
Project Objective
Proposed Phase 1 study completed
Major Proposed Activities
Conduct a Phase 1 study to evaluate IO-202 in relapsed/refractory patients with AML with monocytic differentiation and CMML.
Statement of Benefit to California:
Evaluating IO-202, a first-in-class therapeutic, in this Phase 1 study will generate a wealth of new scientific data on the biology of a novel target LILRB4, and provide a greater understanding of the pathology and clinical outcomes for AML with monocytic differentiation and CMML. If successful, the development of IO-202 will help prolong patient survival, improve patient quality of life, reduce the economic burden of AML and CMML and the personal burden on caregivers and relatives.
